Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC).
2018 ◽
Vol 36
(15_suppl)
◽
pp. 9072-9072
◽
Keyword(s):
Phase Ii
◽